NCT04668300View on ClinicalTrials.gov

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 26, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Metastatic AngiosarcomaMetastatic Dedifferentiated LiposarcomaMetastatic OsteosarcomaRecurrent AngiosarcomaRecurrent Dedifferentiated LiposarcomaRecurrent OsteosarcomaRefractory Dedifferentiated LiposarcomaRefractory Osteosarcoma
Interventions
BIOLOGICAL

Durvalumab

Given IV

BIOLOGICAL

Oleclumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER